IMR Press / FBL / Volume 10 / Issue 1 / DOI: 10.2741/1506

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Citrullinated proteins in rheumatoid arthritis
Show Less
1 Laboratory for Rheumatic Diseases, SNP Research Center, Riken, Yokohama, Japan
Front. Biosci. (Landmark Ed) 2005, 10(1), 54–64; https://doi.org/10.2741/1506
Published: 1 January 2005
Abstract

Citrullinated proteins that are produced by enzymatic deimination of arginine residues in proteins by peptidylarginine deiminases (PADIs) are of particular interest in the pathogenesis of rheumatoid arthritis (RA). First, peptidylarginine deiminase type 4 (PADI4) gene, which codes one of the PADI enzyme isotypes, has a genetic variant that increases susceptibility to RA. The RA-susceptible variant of PADI4 seems to increase the risk of RA by increasing its enzymatic activity. Second, this post-translational protein modification unfolds proteins by loss of a positive charge in arginine residues, with a subsequent change in antigenicity of the self-proteins. Third, these citrullinated proteins are recognized by anti-citrullinated peptide antibodies that are the most RA-specific autoantibodies. Finally, the expression of the PADI enzyme, citrullination of proteins, and production of anti-citrullinated protein antibodies occur in synovium. These data suggest that citrullination of proteins by PADI is related to alteration of antigenicity of peptides and very closely linked to pathogenesis of RA autoimmunity.

Keywords
Rheumatoid Arthritis
PADI4
Citrulline
Anti-Citrullinated Peptide Antibody
Review
Share
Back to top